Plecanatide vs Efinopegdutide
Head-to-head comparison of Plecanatide (Plecanatide) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Efinopegdutide |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Plecanatide | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | Approx. 1620 Da | N/A |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | Approximately 1 week |
| Amino Acids | 16 | N/A |
| Typical Dose | 3 mg once daily | Trial-dependent; weekly SC dosing |
| Route | Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 14 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.